424 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp00322 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Epithelial cancer | CC50 : 46.2 ± 7.6 μM |
| dbacp00323 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Chronic myeloid Leukemia | CC50 : 46.2 ± 7.6 μM |
| dbacp00324 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Gastric cancer | CC50 : 46.2 ± 7.6 μM |
| dbacp00325 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Breast cancer | CC50 : 46.2 ± 7.6 μM |
| dbacp00326 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Cervical cancer | CC50 : 46.2 ± 7.6 μM |
| dbacp00327 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Epithelial cancer | CC50 : 2.3 ± 0.2 μM |
| dbacp00328 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Chronic myeloid Leukemia | CC50 : 2.3 ± 0.2 μM |
| dbacp00329 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Gastric cancer | CC50 : 2.3 ± 0.2 μM |
| dbacp00330 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Breast cancer | CC50 : 2.3 ± 0.2 μM |
| dbacp00331 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Cervical cancer | CC50 : 2.3 ± 0.2 μM |
| dbacp00332 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Epithelial cancer | CC50 : 30.8 ± 2.0 μM |
| dbacp00333 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Chronic myeloid Leukemia | CC50 : 30.8 ± 2.0 μM |
| dbacp00334 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Gastric cancer | CC50 : 30.8 ± 2.0 μM |
| dbacp00335 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Breast cancer | CC50 : 30.8 ± 2.0 μM |
| dbacp00336 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Cervical cancer | CC50 : 30.8 ± 2.0 μM |
| dbacp00337 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Epithelial cancer | CC50 : 36.2 ± 2.8 μM |
| dbacp00338 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Chronic myeloid Leukemia | CC50 : 36.2 ± 2.8 μM |
| dbacp00339 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Gastric cancer | CC50 : 36.2 ± 2.8 μM |
| dbacp00340 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Breast cancer | CC50 : 36.2 ± 2.8 μM |
| dbacp00341 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Cervical cancer | CC50 : 36.2 ± 2.8 μM |
| dbacp00342 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Epithelial cancer | CC50 : 29.0 ± 3.7 μM |
| dbacp00343 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Chronic myeloid Leukemia | CC50 : 29.0 ± 3.7 μM |
| dbacp00344 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Gastric cancer | CC50 : 29.0 ± 3.7 μM |
| dbacp00345 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Breast cancer | CC50 : 29.0 ± 3.7 μM |
| dbacp00346 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Cervical cancer | CC50 : 29.0 ± 3.7 μM |
| dbacp00347 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Epithelial cancer | CC50 : 6.4 ± 0.6 μM |
| dbacp00348 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Chronic myeloid Leukemia | CC50 : 6.4 ± 0.6 μM |
| dbacp00349 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Gastric cancer | CC50 : 6.4 ± 0.6 μM |
| dbacp00350 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Breast cancer | CC50 : 6.4 ± 0.6 μM |
| dbacp00351 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Cervical cancer | CC50 : 6.4 ± 0.6 μM |
| dbacp00352 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Epithelial cancer | CC50 : 33.3 ±7.4 μM |
| dbacp00353 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Chronic myeloid Leukemia | CC50 : 33.3 ±7.4 μM |
| dbacp00354 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Gastric cancer | CC50 : 33.3 ±7.4 μM |
| dbacp00355 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Breast cancer | CC50 : 33.3 ±7.4 μM |
| dbacp00356 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Cervical cancer | CC50 : 33.3 ±7.4 μM |
| dbacp00357 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Epithelial cancer | CC50 : 9.5 ± 0.5 μM |
| dbacp00358 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Chronic myeloid Leukemia | CC50 : 9.5 ± 0.5 μM |
| dbacp00359 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Gastric cancer | CC50 : 9.5 ± 0.5 μM |
| dbacp00360 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Breast cancer | CC50 : 9.5 ± 0.5 μM |
| dbacp00361 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Cervical cancer | CC50 : 9.5 ± 0.5 μM |
| dbacp00362 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Epithelial cancer | CC50 : 51.0 ± 4.6 μM |
| dbacp00363 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Chronic myeloid Leukemia | CC50 : 51.0 ± 4.6 μM |
| dbacp00364 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Gastric cancer | CC50 : 51.0 ± 4.6 μM |
| dbacp00365 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Breast cancer | CC50 : 51.0 ± 4.6 μM |
| dbacp00366 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Cervical cancer | CC50 : 51.0 ± 4.6 μM |
| dbacp00367 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Epithelial cancer | CC50 : 4.6 ± 0.2 μM |
| dbacp00368 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Chronic myeloid Leukemia | CC50 : 4.6 ± 0.2 μM |
| dbacp00369 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Gastric cancer | CC50 : 4.6 ± 0.2 μM |
| dbacp00370 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Breast cancer | CC50 : 4.6 ± 0.2 μM |
| dbacp00371 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Cervical cancer | CC50 : 4.6 ± 0.2 μM |
| dbacp00372 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Epithelial cancer | CC50 : 15.6 ± 3.6 μM |
| dbacp00373 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Chronic myeloid Leukemia | CC50 : 15.6 ± 3.6 μM |
| dbacp00374 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Gastric cancer | CC50 : 15.6 ± 3.6 μM |
| dbacp00375 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Breast cancer | CC50 : 15.6 ± 3.6 μM |
| dbacp00376 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Cervical cancer | CC50 : 15.6 ± 3.6 μM |
| dbacp00377 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Epithelial cancer | CC50 : > 64 μM |
| dbacp00378 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Chronic myeloid Leukemia | CC50 : > 64 μM |
| dbacp00379 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Gastric cancer | CC50 : > 64 μM |
| dbacp00380 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Breast cancer | CC50 : > 64 μM |
| dbacp00381 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Cervical cancer | CC50 : > 64 μM |
| dbacp00382 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Epithelial cancer | CC50 : 37.5 ± 3.3 μM |
| dbacp00383 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Chronic myeloid Leukemia | CC50 : 37.5 ± 3.3 μM |
| dbacp00384 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Gastric cancer | CC50 : 37.5 ± 3.3 μM |
| dbacp00385 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Breast cancer | CC50 : 37.5 ± 3.3 μM |
| dbacp00386 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Cervical cancer | CC50 : 37.5 ± 3.3 μM |
| dbacp00387 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Epithelial cancer | CC50 : 1.4 ± 0.2 μM |
| dbacp00388 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Chronic myeloid Leukemia | CC50 : 1.4 ± 0.2 μM |
| dbacp00389 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Gastric cancer | CC50 : 1.4 ± 0.2 μM |
| dbacp00390 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Breast cancer | CC50 : 1.4 ± 0.2 μM |
| dbacp00391 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Cervical cancer | CC50 : 1.4 ± 0.2 μM |
| dbacp00392 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Epithelial cancer | CC50 : 38.5 ± 4.8 μM |
| dbacp00393 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Chronic myeloid Leukemia | CC50 : 38.5 ± 4.8 μM |
| dbacp00394 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Gastric cancer | CC50 : 38.5 ± 4.8 μM |
| dbacp00395 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Breast cancer | CC50 : 38.5 ± 4.8 μM |
| dbacp00396 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Cervical cancer | CC50 : 38.5 ± 4.8 μM |
| dbacp00397 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Epithelial cancer | CC50 : 15.5 ± 0.8 μM |
| dbacp00398 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Chronic myeloid Leukemia | CC50 : 15.5 ± 0.8 μM |
| dbacp00399 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Gastric cancer | CC50 : 15.5 ± 0.8 μM |
| dbacp00400 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Breast cancer | CC50 : 15.5 ± 0.8 μM |
| dbacp00401 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Cervical cancer | CC50 : 15.5 ± 0.8 μM |
| dbacp00403 | [D-P L-P]cGm | GCRRLCYKQRCVTYCRGpPR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Epithelial cancer | CC50 : 22.5 ± 3.3 μM |
| dbacp00404 | [D-P L-P]cGm | GCRRLCYKQRCVTYCRGpPR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Chronic myeloid Leukemia | CC50 : 22.5 ± 3.3 μM |
| dbacp00405 | [D-P L-P]cGm | GCRRLCYKQRCVTYCRGpPR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Gastric cancer | CC50 : 22.5 ± 3.3 μM |
| dbacp00406 | [D-P L-P]cGm | GCRRLCYKQRCVTYCRGpPR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Breast cancer | CC50 : 22.5 ± 3.3 μM |
| dbacp00407 | [D-P L-P]cGm | GCRRLCYKQRCVTYCRGpPR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Cervical cancer | CC50 : 22.5 ± 3.3 μM |
| dbacp00408 | [D-P L-P]cGm | GCRRLCYKQRCVTYCRGpPR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Epithelial cancer | CC50 : 3.0 ± 0.1 μM |
| dbacp00409 | [D-P L-P]cGm | GCRRLCYKQRCVTYCRGpPR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Chronic myeloid Leukemia | CC50 : 3.0 ± 0.1 μM |
| dbacp00410 | [D-P L-P]cGm | GCRRLCYKQRCVTYCRGpPR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Gastric cancer | CC50 : 3.0 ± 0.1 μM |
| dbacp00411 | [D-P L-P]cGm | GCRRLCYKQRCVTYCRGpPR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Breast cancer | CC50 : 3.0 ± 0.1 μM |
| dbacp00412 | [D-P L-P]cGm | GCRRLCYKQRCVTYCRGpPR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Cervical cancer | CC50 : 3.0 ± 0.1 μM |
| dbacp00413 | [D-P L-P]cGm | GCRRLCYKQRCVTYCRGpPR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Epithelial cancer | CC50 : 14.9 ± 0.8 μM |
| dbacp00414 | [D-P L-P]cGm | GCRRLCYKQRCVTYCRGpPR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Chronic myeloid Leukemia | CC50 : 14.9 ± 0.8 μM |
| dbacp00415 | [D-P L-P]cGm | GCRRLCYKQRCVTYCRGpPR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Gastric cancer | CC50 : 14.9 ± 0.8 μM |
| dbacp00416 | [D-P L-P]cGm | GCRRLCYKQRCVTYCRGpPR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Breast cancer | CC50 : 14.9 ± 0.8 μM |
| dbacp00417 | [D-P L-P]cGm | GCRRLCYKQRCVTYCRGpPR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Cervical cancer | CC50 : 14.9 ± 0.8 μM |
| dbacp00418 | [D-P L-P]cGm | GCRRLCYKQRCVTYCRGpPR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Epithelial cancer | CC50 : 51.5 ± 3.9 μM |
| dbacp00419 | [D-P L-P]cGm | GCRRLCYKQRCVTYCRGpPR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Chronic myeloid Leukemia | CC50 : 51.5 ± 3.9 μM |
| dbacp00420 | [D-P L-P]cGm | GCRRLCYKQRCVTYCRGpPR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Gastric cancer | CC50 : 51.5 ± 3.9 μM |
| dbacp00421 | [D-P L-P]cGm | GCRRLCYKQRCVTYCRGpPR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Breast cancer | CC50 : 51.5 ± 3.9 μM |
| dbacp00422 | [D-P L-P]cGm | GCRRLCYKQRCVTYCRGpPR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Cervical cancer | CC50 : 51.5 ± 3.9 μM |
| dbacp00423 | [D-P L-P]cGm | GCRRLCYKQRCVTYCRGpPR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Epithelial cancer | CC50 : 3.9 ± 0.2 μM |
| dbacp00424 | [D-P L-P]cGm | GCRRLCYKQRCVTYCRGpPR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Chronic myeloid Leukemia | CC50 : 3.9 ± 0.2 μM |
| dbacp00425 | [D-P L-P]cGm | GCRRLCYKQRCVTYCRGpPR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Gastric cancer | CC50 : 3.9 ± 0.2 μM |
| dbacp00426 | [D-P L-P]cGm | GCRRLCYKQRCVTYCRGpPR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Breast cancer | CC50 : 3.9 ± 0.2 μM |
| dbacp00427 | [D-P L-P]cGm | GCRRLCYKQRCVTYCRGpPR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Cervical cancer | CC50 : 3.9 ± 0.2 μM |
| dbacp00428 | [D-P L-P]cGm | GCRRLCYKQRCVTYCRGpPR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Epithelial cancer | CC50 : 14.1 ± 0.9 μM |
| dbacp00429 | [D-P L-P]cGm | GCRRLCYKQRCVTYCRGpPR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Chronic myeloid Leukemia | CC50 : 14.1 ± 0.9 μM |
| dbacp00430 | [D-P L-P]cGm | GCRRLCYKQRCVTYCRGpPR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Gastric cancer | CC50 : 14.1 ± 0.9 μM |
| dbacp00431 | [D-P L-P]cGm | GCRRLCYKQRCVTYCRGpPR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Breast cancer | CC50 : 14.1 ± 0.9 μM |
| dbacp00432 | [D-P L-P]cGm | GCRRLCYKQRCVTYCRGpPR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Cervical cancer | CC50 : 14.1 ± 0.9 μM |
| dbacp00440 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Epithelial cancer | CC50 : 19.5 ± 0.5 μM |
| dbacp00441 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Chronic myeloid Leukemia | CC50 : 19.5 ± 0.5 μM |
| dbacp00442 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Gastric cancer | CC50 : 19.5 ± 0.5 μM |
| dbacp00443 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Breast cancer | CC50 : 19.5 ± 0.5 μM |
| dbacp00444 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Cervical cancer | CC50 : 19.5 ± 0.5 μM |
| dbacp00445 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Epithelial cancer | CC50 : 1.7 ± 0.1 μM |
| dbacp00446 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Chronic myeloid Leukemia | CC50 : 1.7 ± 0.1 μM |
| dbacp00447 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Gastric cancer | CC50 : 1.7 ± 0.1 μM |
| dbacp00448 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Breast cancer | CC50 : 1.7 ± 0.1 μM |
| dbacp00449 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Cervical cancer | CC50 : 1.7 ± 0.1 μM |
| dbacp00450 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Epithelial cancer | CC50 : 9.0 ± 0.5 μM |
| dbacp00451 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Chronic myeloid Leukemia | CC50 : 9.0 ± 0.5 μM |
| dbacp00452 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Gastric cancer | CC50 : 9.0 ± 0.5 μM |
| dbacp00453 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Breast cancer | CC50 : 9.0 ± 0.5 μM |
| dbacp00454 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Cervical cancer | CC50 : 9.0 ± 0.5 μM |
| dbacp00455 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Epithelial cancer | CC50 : 44.2 ± 2.2 μM |
| dbacp00456 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Chronic myeloid Leukemia | CC50 : 44.2 ± 2.2 μM |
| dbacp00457 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Gastric cancer | CC50 : 44.2 ± 2.2 μM |
| dbacp00458 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Breast cancer | CC50 : 44.2 ± 2.2 μM |
| dbacp00459 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Cervical cancer | CC50 : 44.2 ± 2.2 μM |
| dbacp00460 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Epithelial cancer | CC50 : 6.7 ± 0.7 μM |
| dbacp00461 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Chronic myeloid Leukemia | CC50 : 6.7 ± 0.7 μM |
| dbacp00462 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Gastric cancer | CC50 : 6.7 ± 0.7 μM |
| dbacp00463 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Breast cancer | CC50 : 6.7 ± 0.7 μM |
| dbacp00464 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Cervical cancer | CC50 : 6.7 ± 0.7 μM |
| dbacp00465 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Epithelial cancer | CC50 : 2.1 ± 0.2 μM |
| dbacp00466 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Chronic myeloid Leukemia | CC50 : 2.1 ± 0.2 μM |
| dbacp00467 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Gastric cancer | CC50 : 2.1 ± 0.2 μM |
| dbacp00468 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Breast cancer | CC50 : 2.1 ± 0.2 μM |
| dbacp00469 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Cervical cancer | CC50 : 2.1 ± 0.2 μM |
| dbacp00470 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Epithelial cancer | CC50 : 9.0 ± 1.1μM |
| dbacp00471 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Chronic myeloid Leukemia | CC50 : 9.0 ± 1.1μM |
| dbacp00472 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Gastric cancer | CC50 : 9.0 ± 1.1μM |
| dbacp00473 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Breast cancer | CC50 : 9.0 ± 1.1μM |
| dbacp00474 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Cervical cancer | CC50 : 9.0 ± 1.1μM |
| dbacp00475 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Epithelial cancer | CC50 : 5.1 ± 0.3 μM |
| dbacp00476 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Chronic myeloid Leukemia | CC50 : 5.1 ± 0.3 μM |
| dbacp00477 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Gastric cancer | CC50 : 5.1 ± 0.3 μM |
| dbacp00478 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Breast cancer | CC50 : 5.1 ± 0.3 μM |
| dbacp00479 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Cervical cancer | CC50 : 5.1 ± 0.3 μM |
| dbacp00480 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Epithelial cancer | CC50 : 26.5 ± 2.4 μM |
| dbacp00481 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Chronic myeloid Leukemia | CC50 : 26.5 ± 2.4 μM |
| dbacp00482 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Gastric cancer | CC50 : 26.5 ± 2.4 μM |
| dbacp00483 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Breast cancer | CC50 : 26.5 ± 2.4 μM |
| dbacp00484 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Cervical cancer | CC50 : 26.5 ± 2.4 μM |
| dbacp00485 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Epithelial cancer | CC50 : 2.0 ± 0.1 μM |
| dbacp00486 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Chronic myeloid Leukemia | CC50 : 2.0 ± 0.1 μM |
| dbacp00487 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Gastric cancer | CC50 : 2.0 ± 0.1 μM |
| dbacp00488 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Breast cancer | CC50 : 2.0 ± 0.1 μM |
| dbacp00489 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Cervical cancer | CC50 : 2.0 ± 0.1 μM |
| dbacp00490 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Epithelial cancer | CC50 : 14.7 ± 1.5 μM |
| dbacp00491 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Chronic myeloid Leukemia | CC50 : 14.7 ± 1.5 μM |
| dbacp00492 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Gastric cancer | CC50 : 14.7 ± 1.5 μM |
| dbacp00493 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Breast cancer | CC50 : 14.7 ± 1.5 μM |
| dbacp00494 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Cervical cancer | CC50 : 14.7 ± 1.5 μM |
| dbacp00495 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Epithelial cancer | CC50 : 20.9 ± 1.4 μM |
| dbacp00496 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Chronic myeloid Leukemia | CC50 : 20.9 ± 1.4 μM |
| dbacp00497 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Gastric cancer | CC50 : 20.9 ± 1.4 μM |
| dbacp00498 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Breast cancer | CC50 : 20.9 ± 1.4 μM |
| dbacp00499 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Cervical cancer | CC50 : 20.9 ± 1.4 μM |
| dbacp00500 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Epithelial cancer | CC50 : 15.2 ± 1.9 μM |
| dbacp00501 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Chronic myeloid Leukemia | CC50 : 15.2 ± 1.9 μM |
| dbacp00502 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Gastric cancer | CC50 : 15.2 ± 1.9 μM |
| dbacp00503 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Breast cancer | CC50 : 15.2 ± 1.9 μM |
| dbacp00504 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Cervical cancer | CC50 : 15.2 ± 1.9 μM |
| dbacp00505 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Epithelial cancer | CC50 : 1.3 ± 0.1 μM |
| dbacp00506 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Chronic myeloid Leukemia | CC50 : 1.3 ± 0.1 μM |
| dbacp00507 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Gastric cancer | CC50 : 1.3 ± 0.1 μM |
| dbacp00508 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Breast cancer | CC50 : 1.3 ± 0.1 μM |
| dbacp00509 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Cervical cancer | CC50 : 1.3 ± 0.1 μM |
| dbacp00510 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Epithelial cancer | CC50 : 15.7 ±1.1μM |
| dbacp00511 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Chronic myeloid Leukemia | CC50 : 15.7 ±1.1μM |
| dbacp00512 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Gastric cancer | CC50 : 15.7 ±1.1μM |
| dbacp00513 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Breast cancer | CC50 : 15.7 ±1.1μM |
| dbacp00514 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Cervical cancer | CC50 : 15.7 ±1.1μM |
| dbacp00515 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Epithelial cancer | CC50 : 10.4 ± 1.0 μM |
| dbacp00516 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Chronic myeloid Leukemia | CC50 : 10.4 ± 1.0 μM |
| dbacp00517 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Gastric cancer | CC50 : 10.4 ± 1.0 μM |
| dbacp00518 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Breast cancer | CC50 : 10.4 ± 1.0 μM |
| dbacp00519 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Cervical cancer | CC50 : 10.4 ± 1.0 μM |
| dbacp00520 | [K8R]cGm | GCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Epithelial cancer | CC50 : 29.4 ± 1.1 μM |
| dbacp00521 | [K8R]cGm | GCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Chronic myeloid Leukemia | CC50 : 29.4 ± 1.1 μM |
| dbacp00522 | [K8R]cGm | GCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Gastric cancer | CC50 : 29.4 ± 1.1 μM |
| dbacp00523 | [K8R]cGm | GCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Breast cancer | CC50 : 29.4 ± 1.1 μM |
| dbacp00524 | [K8R]cGm | GCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Cervical cancer | CC50 : 29.4 ± 1.1 μM |
| dbacp00525 | [K8R]cGm | GCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Epithelial cancer | CC50 : 5.0 ± 0.3 μM |
| dbacp00526 | [K8R]cGm | GCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Chronic myeloid Leukemia | CC50 : 5.0 ± 0.3 μM |
| dbacp00527 | [K8R]cGm | GCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Gastric cancer | CC50 : 5.0 ± 0.3 μM |
| dbacp00528 | [K8R]cGm | GCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Breast cancer | CC50 : 5.0 ± 0.3 μM |
| dbacp00529 | [K8R]cGm | GCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Cervical cancer | CC50 : 5.0 ± 0.3 μM |
| dbacp00530 | [K8R]cGm | GCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Epithelial cancer | CC50 : 34.5 ± 3.6 μM |
| dbacp00531 | [K8R]cGm | GCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Chronic myeloid Leukemia | CC50 : 34.5 ± 3.6 μM |
| dbacp00532 | [K8R]cGm | GCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Gastric cancer | CC50 : 34.5 ± 3.6 μM |
| dbacp00533 | [K8R]cGm | GCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Breast cancer | CC50 : 34.5 ± 3.6 μM |
| dbacp00534 | [K8R]cGm | GCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Cervical cancer | CC50 : 34.5 ± 3.6 μM |
| dbacp00535 | [K8R]cGm | GCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Epithelial cancer | CC50 : 39.4 ± 2.6 μM |
| dbacp00536 | [K8R]cGm | GCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Chronic myeloid Leukemia | CC50 : 39.4 ± 2.6 μM |
| dbacp00537 | [K8R]cGm | GCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Gastric cancer | CC50 : 39.4 ± 2.6 μM |
| dbacp00538 | [K8R]cGm | GCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Breast cancer | CC50 : 39.4 ± 2.6 μM |
| dbacp00539 | [K8R]cGm | GCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Cervical cancer | CC50 : 39.4 ± 2.6 μM |
| dbacp00540 | [K8R]cGm | GCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Epithelial cancer | CC50 : 3.1 ± 0.1 μM |
| dbacp00541 | [K8R]cGm | GCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Chronic myeloid Leukemia | CC50 : 3.1 ± 0.1 μM |
| dbacp00542 | [K8R]cGm | GCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Gastric cancer | CC50 : 3.1 ± 0.1 μM |
| dbacp00543 | [K8R]cGm | GCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Breast cancer | CC50 : 3.1 ± 0.1 μM |
| dbacp00544 | [K8R]cGm | GCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Cervical cancer | CC50 : 3.1 ± 0.1 μM |
| dbacp00545 | [L5W]cGm | GCRRWCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Epithelial cancer | CC50 : 18.3 ± 1.4 μM |
| dbacp00546 | [L5W]cGm | GCRRWCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Chronic myeloid Leukemia | CC50 : 18.3 ± 1.4 μM |
| dbacp00547 | [L5W]cGm | GCRRWCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Gastric cancer | CC50 : 18.3 ± 1.4 μM |
| dbacp00548 | [L5W]cGm | GCRRWCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Breast cancer | CC50 : 18.3 ± 1.4 μM |
| dbacp00549 | [L5W]cGm | GCRRWCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Cervical cancer | CC50 : 18.3 ± 1.4 μM |
| dbacp00550 | [L5W]cGm | GCRRWCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Epithelial cancer | CC50 : 4.0 ± 0.1 μM |
| dbacp00551 | [L5W]cGm | GCRRWCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Chronic myeloid Leukemia | CC50 : 4.0 ± 0.1 μM |
| dbacp00552 | [L5W]cGm | GCRRWCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Gastric cancer | CC50 : 4.0 ± 0.1 μM |
| dbacp00553 | [L5W]cGm | GCRRWCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Breast cancer | CC50 : 4.0 ± 0.1 μM |
| dbacp00554 | [L5W]cGm | GCRRWCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Cervical cancer | CC50 : 4.0 ± 0.1 μM |
| dbacp00555 | [L5W]cGm | GCRRWCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Epithelial cancer | CC50 : 25.0 ± 2.9 μM |
| dbacp00556 | [L5W]cGm | GCRRWCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Chronic myeloid Leukemia | CC50 : 25.0 ± 2.9 μM |
| dbacp00557 | [L5W]cGm | GCRRWCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Gastric cancer | CC50 : 25.0 ± 2.9 μM |
| dbacp00558 | [L5W]cGm | GCRRWCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Breast cancer | CC50 : 25.0 ± 2.9 μM |
| dbacp00559 | [L5W]cGm | GCRRWCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Cervical cancer | CC50 : 25.0 ± 2.9 μM |
| dbacp00560 | [L5W]cGm | GCRRWCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Epithelial cancer | CC50 : 17.1 ± 0.7 μM |
| dbacp00561 | [L5W]cGm | GCRRWCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Chronic myeloid Leukemia | CC50 : 17.1 ± 0.7 μM |
| dbacp00562 | [L5W]cGm | GCRRWCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Gastric cancer | CC50 : 17.1 ± 0.7 μM |
| dbacp00563 | [L5W]cGm | GCRRWCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Breast cancer | CC50 : 17.1 ± 0.7 μM |
| dbacp00564 | [L5W]cGm | GCRRWCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Cervical cancer | CC50 : 17.1 ± 0.7 μM |
| dbacp00565 | [L5W]cGm | GCRRWCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Epithelial cancer | CC50 : 1.0 ± 0.1 μM |
| dbacp00566 | [L5W]cGm | GCRRWCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Chronic myeloid Leukemia | CC50 : 1.0 ± 0.1 μM |
| dbacp00567 | [L5W]cGm | GCRRWCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Gastric cancer | CC50 : 1.0 ± 0.1 μM |
| dbacp00568 | [L5W]cGm | GCRRWCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Breast cancer | CC50 : 1.0 ± 0.1 μM |
| dbacp00569 | [L5W]cGm | GCRRWCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Cervical cancer | CC50 : 1.0 ± 0.1 μM |
| dbacp00573 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Epithelial cancer | CC50 : > 64 μM |
| dbacp00574 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Chronic myeloid Leukemia | CC50 : > 64 μM |
| dbacp00575 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Gastric cancer | CC50 : > 64 μM |
| dbacp00576 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Breast cancer | CC50 : > 64 μM |
| dbacp00577 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Cervical cancer | CC50 : > 64 μM |
| dbacp00578 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Epithelial cancer | CC50 : 10.3 ± 1.1 μM |
| dbacp00579 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Chronic myeloid Leukemia | CC50 : 10.3 ± 1.1 μM |
| dbacp00580 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Gastric cancer | CC50 : 10.3 ± 1.1 μM |
| dbacp00581 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Breast cancer | CC50 : 10.3 ± 1.1 μM |
| dbacp00582 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Cervical cancer | CC50 : 10.3 ± 1.1 μM |
| dbacp00583 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Epithelial cancer | CC50 : 51.2 ± 4.0 μM |
| dbacp00584 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Chronic myeloid Leukemia | CC50 : 51.2 ± 4.0 μM |
| dbacp00585 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Gastric cancer | CC50 : 51.2 ± 4.0 μM |
| dbacp00586 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Breast cancer | CC50 : 51.2 ± 4.0 μM |
| dbacp00587 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Cervical cancer | CC50 : 51.2 ± 4.0 μM |
| dbacp00588 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Epithelial cancer | CC50 : > 64 μM |
| dbacp00589 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Chronic myeloid Leukemia | CC50 : > 64 μM |
| dbacp00590 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Gastric cancer | CC50 : > 64 μM |
| dbacp00591 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Breast cancer | CC50 : > 64 μM |
| dbacp00592 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Cervical cancer | CC50 : > 64 μM |
| dbacp00593 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Epithelial cancer | CC50 : 48.4 ± 0.7 μM |
| dbacp00594 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Chronic myeloid Leukemia | CC50 : 48.4 ± 0.7 μM |
| dbacp00595 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Gastric cancer | CC50 : 48.4 ± 0.7 μM |
| dbacp00596 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Breast cancer | CC50 : 48.4 ± 0.7 μM |
| dbacp00597 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Cervical cancer | CC50 : 48.4 ± 0.7 μM |
| dbacp00598 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Epithelial cancer | CC50 : 11.5 ± 0.6 μM |
| dbacp00599 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Chronic myeloid Leukemia | CC50 : 11.5 ± 0.6 μM |
| dbacp00600 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Gastric cancer | CC50 : 11.5 ± 0.6 μM |
| dbacp00601 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Breast cancer | CC50 : 11.5 ± 0.6 μM |
| dbacp00602 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Cervical cancer | CC50 : 11.5 ± 0.6 μM |
| dbacp00603 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Epithelial cancer | CC50 : 34.1 ± 3.9 μM |
| dbacp00604 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Chronic myeloid Leukemia | CC50 : 34.1 ± 3.9 μM |
| dbacp00605 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Gastric cancer | CC50 : 34.1 ± 3.9 μM |
| dbacp00606 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Breast cancer | CC50 : 34.1 ± 3.9 μM |
| dbacp00607 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Cervical cancer | CC50 : 34.1 ± 3.9 μM |
| dbacp00608 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Epithelial cancer | CC50 : 30.8 ± 2.5 μM |
| dbacp00609 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Chronic myeloid Leukemia | CC50 : 30.8 ± 2.5 μM |
| dbacp00610 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Gastric cancer | CC50 : 30.8 ± 2.5 μM |
| dbacp00611 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Breast cancer | CC50 : 30.8 ± 2.5 μM |
| dbacp00612 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Cervical cancer | CC50 : 30.8 ± 2.5 μM |
| dbacp00621 | [Y14W]cGm | GCRRLCYKQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Epithelial cancer | CC50 : 30.3 ± 1.1 μM |
| dbacp00622 | [Y14W]cGm | GCRRLCYKQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Chronic myeloid Leukemia | CC50 : 30.3 ± 1.1 μM |
| dbacp00623 | [Y14W]cGm | GCRRLCYKQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Gastric cancer | CC50 : 30.3 ± 1.1 μM |
| dbacp00624 | [Y14W]cGm | GCRRLCYKQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Breast cancer | CC50 : 30.3 ± 1.1 μM |
| dbacp00625 | [Y14W]cGm | GCRRLCYKQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Cervical cancer | CC50 : 30.3 ± 1.1 μM |
| dbacp00626 | [Y14W]cGm | GCRRLCYKQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Epithelial cancer | CC50 : 4.0 ± 0.1 μM |
| dbacp00627 | [Y14W]cGm | GCRRLCYKQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Chronic myeloid Leukemia | CC50 : 4.0 ± 0.1 μM |
| dbacp00628 | [Y14W]cGm | GCRRLCYKQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Gastric cancer | CC50 : 4.0 ± 0.1 μM |
| dbacp00629 | [Y14W]cGm | GCRRLCYKQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Breast cancer | CC50 : 4.0 ± 0.1 μM |
| dbacp00630 | [Y14W]cGm | GCRRLCYKQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Cervical cancer | CC50 : 4.0 ± 0.1 μM |
| dbacp00631 | [Y14W]cGm | GCRRLCYKQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Epithelial cancer | CC50 : 68.4 ± 9.6 μM |
| dbacp00632 | [Y14W]cGm | GCRRLCYKQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Chronic myeloid Leukemia | CC50 : 68.4 ± 9.6 μM |
| dbacp00633 | [Y14W]cGm | GCRRLCYKQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Gastric cancer | CC50 : 68.4 ± 9.6 μM |
| dbacp00634 | [Y14W]cGm | GCRRLCYKQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Breast cancer | CC50 : 68.4 ± 9.6 μM |
| dbacp00635 | [Y14W]cGm | GCRRLCYKQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Cervical cancer | CC50 : 68.4 ± 9.6 μM |
| dbacp00636 | [Y14W]cGm | GCRRLCYKQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Epithelial cancer | CC50 : 50.4 ± 2.4 μM |
| dbacp00637 | [Y14W]cGm | GCRRLCYKQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Chronic myeloid Leukemia | CC50 : 50.4 ± 2.4 μM |
| dbacp00638 | [Y14W]cGm | GCRRLCYKQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Gastric cancer | CC50 : 50.4 ± 2.4 μM |
| dbacp00639 | [Y14W]cGm | GCRRLCYKQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Breast cancer | CC50 : 50.4 ± 2.4 μM |
| dbacp00640 | [Y14W]cGm | GCRRLCYKQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Cervical cancer | CC50 : 50.4 ± 2.4 μM |
| dbacp00641 | [Y14W]cGm | GCRRLCYKQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Epithelial cancer | CC50 : 2.7 ± 0.1 μM |
| dbacp00642 | [Y14W]cGm | GCRRLCYKQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Chronic myeloid Leukemia | CC50 : 2.7 ± 0.1 μM |
| dbacp00643 | [Y14W]cGm | GCRRLCYKQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Gastric cancer | CC50 : 2.7 ± 0.1 μM |
| dbacp00644 | [Y14W]cGm | GCRRLCYKQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Breast cancer | CC50 : 2.7 ± 0.1 μM |
| dbacp00645 | [Y14W]cGm | GCRRLCYKQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Cervical cancer | CC50 : 2.7 ± 0.1 μM |
| dbacp00646 | [Y7W, K8R, Y14W]cGm | GCRRLCWRQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Epithelial cancer | CC50 : 31.6 ± 1.3 μM |
| dbacp00647 | [Y7W, K8R, Y14W]cGm | GCRRLCWRQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Chronic myeloid Leukemia | CC50 : 31.6 ± 1.3 μM |
| dbacp00648 | [Y7W, K8R, Y14W]cGm | GCRRLCWRQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Gastric cancer | CC50 : 31.6 ± 1.3 μM |
| dbacp00649 | [Y7W, K8R, Y14W]cGm | GCRRLCWRQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Breast cancer | CC50 : 31.6 ± 1.3 μM |
| dbacp00650 | [Y7W, K8R, Y14W]cGm | GCRRLCWRQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Cervical cancer | CC50 : 31.6 ± 1.3 μM |
| dbacp00651 | [Y7W, K8R, Y14W]cGm | GCRRLCWRQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Epithelial cancer | CC50 : 5.4 ± 0.3 μM |
| dbacp00652 | [Y7W, K8R, Y14W]cGm | GCRRLCWRQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Chronic myeloid Leukemia | CC50 : 5.4 ± 0.3 μM |
| dbacp00653 | [Y7W, K8R, Y14W]cGm | GCRRLCWRQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Gastric cancer | CC50 : 5.4 ± 0.3 μM |
| dbacp00654 | [Y7W, K8R, Y14W]cGm | GCRRLCWRQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Breast cancer | CC50 : 5.4 ± 0.3 μM |
| dbacp00655 | [Y7W, K8R, Y14W]cGm | GCRRLCWRQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Cervical cancer | CC50 : 5.4 ± 0.3 μM |
| dbacp00656 | [Y7W, K8R, Y14W]cGm | GCRRLCWRQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Epithelial cancer | CC50 : 31.3 ± 2.6 μM |
| dbacp00657 | [Y7W, K8R, Y14W]cGm | GCRRLCWRQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Chronic myeloid Leukemia | CC50 : 31.3 ± 2.6 μM |
| dbacp00658 | [Y7W, K8R, Y14W]cGm | GCRRLCWRQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Gastric cancer | CC50 : 31.3 ± 2.6 μM |
| dbacp00659 | [Y7W, K8R, Y14W]cGm | GCRRLCWRQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Breast cancer | CC50 : 31.3 ± 2.6 μM |
| dbacp00660 | [Y7W, K8R, Y14W]cGm | GCRRLCWRQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Cervical cancer | CC50 : 31.3 ± 2.6 μM |
| dbacp00661 | [Y7W, K8R, Y14W]cGm | GCRRLCWRQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Epithelial cancer | CC50 : 41.0 ± 4.2 μM |
| dbacp00662 | [Y7W, K8R, Y14W]cGm | GCRRLCWRQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Chronic myeloid Leukemia | CC50 : 41.0 ± 4.2 μM |
| dbacp00663 | [Y7W, K8R, Y14W]cGm | GCRRLCWRQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Gastric cancer | CC50 : 41.0 ± 4.2 μM |
| dbacp00664 | [Y7W, K8R, Y14W]cGm | GCRRLCWRQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Breast cancer | CC50 : 41.0 ± 4.2 μM |
| dbacp00665 | [Y7W, K8R, Y14W]cGm | GCRRLCWRQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Cervical cancer | CC50 : 41.0 ± 4.2 μM |
| dbacp00666 | [Y7W, K8R, Y14W]cGm | GCRRLCWRQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Epithelial cancer | CC50 : 15.1 ± 1.4 μM |
| dbacp00667 | [Y7W, K8R, Y14W]cGm | GCRRLCWRQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Chronic myeloid Leukemia | CC50 : 15.1 ± 1.4 μM |
| dbacp00668 | [Y7W, K8R, Y14W]cGm | GCRRLCWRQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Gastric cancer | CC50 : 15.1 ± 1.4 μM |
| dbacp00669 | [Y7W, K8R, Y14W]cGm | GCRRLCWRQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Breast cancer | CC50 : 15.1 ± 1.4 μM |
| dbacp00670 | [Y7W, K8R, Y14W]cGm | GCRRLCWRQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Cervical cancer | CC50 : 15.1 ± 1.4 μM |
| dbacp00671 | [Y7W, K8R, Y14W]cGm | GCRRLCWRQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Epithelial cancer | CC50 : 3.9 ± 0.1 μM |
| dbacp00672 | [Y7W, K8R, Y14W]cGm | GCRRLCWRQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Chronic myeloid Leukemia | CC50 : 3.9 ± 0.1 μM |
| dbacp00673 | [Y7W, K8R, Y14W]cGm | GCRRLCWRQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Gastric cancer | CC50 : 3.9 ± 0.1 μM |
| dbacp00674 | [Y7W, K8R, Y14W]cGm | GCRRLCWRQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Breast cancer | CC50 : 3.9 ± 0.1 μM |
| dbacp00675 | [Y7W, K8R, Y14W]cGm | GCRRLCWRQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Cervical cancer | CC50 : 3.9 ± 0.1 μM |
| dbacp00676 | [Y7W]cGm | GCRRLCWKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Epithelial cancer | CC50 : 23.3 ± 0.4 μM |
| dbacp00677 | [Y7W]cGm | GCRRLCWKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Chronic myeloid Leukemia | CC50 : 23.3 ± 0.4 μM |
| dbacp00678 | [Y7W]cGm | GCRRLCWKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Gastric cancer | CC50 : 23.3 ± 0.4 μM |
| dbacp00679 | [Y7W]cGm | GCRRLCWKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Breast cancer | CC50 : 23.3 ± 0.4 μM |
| dbacp00680 | [Y7W]cGm | GCRRLCWKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Cervical cancer | CC50 : 23.3 ± 0.4 μM |
| dbacp00681 | [Y7W]cGm | GCRRLCWKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Epithelial cancer | CC50 : 5.1 ± 0.3 μM |
| dbacp00682 | [Y7W]cGm | GCRRLCWKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Chronic myeloid Leukemia | CC50 : 5.1 ± 0.3 μM |
| dbacp00683 | [Y7W]cGm | GCRRLCWKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Gastric cancer | CC50 : 5.1 ± 0.3 μM |
| dbacp00684 | [Y7W]cGm | GCRRLCWKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Breast cancer | CC50 : 5.1 ± 0.3 μM |
| dbacp00685 | [Y7W]cGm | GCRRLCWKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Cervical cancer | CC50 : 5.1 ± 0.3 μM |
| dbacp00686 | [Y7W]cGm | GCRRLCWKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Epithelial cancer | CC50 : 39.7 ± 3.8 μM |
| dbacp00687 | [Y7W]cGm | GCRRLCWKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Chronic myeloid Leukemia | CC50 : 39.7 ± 3.8 μM |
| dbacp00688 | [Y7W]cGm | GCRRLCWKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Gastric cancer | CC50 : 39.7 ± 3.8 μM |
| dbacp00689 | [Y7W]cGm | GCRRLCWKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Breast cancer | CC50 : 39.7 ± 3.8 μM |
| dbacp00690 | [Y7W]cGm | GCRRLCWKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Cervical cancer | CC50 : 39.7 ± 3.8 μM |
| dbacp00691 | [Y7W]cGm | GCRRLCWKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Epithelial cancer | CC50 : > 64 μM |
| dbacp00692 | [Y7W]cGm | GCRRLCWKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Chronic myeloid Leukemia | CC50 : > 64 μM |
| dbacp00693 | [Y7W]cGm | GCRRLCWKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Gastric cancer | CC50 : > 64 μM |
| dbacp00694 | [Y7W]cGm | GCRRLCWKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Breast cancer | CC50 : > 64 μM |
| dbacp00695 | [Y7W]cGm | GCRRLCWKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Cervical cancer | CC50 : > 64 μM |
| dbacp00696 | [Y7W]cGm | GCRRLCWKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Epithelial cancer | CC50 : 3.9 ± 0.2 μM |
| dbacp00697 | [Y7W]cGm | GCRRLCWKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Chronic myeloid Leukemia | CC50 : 3.9 ± 0.2 μM |
| dbacp00698 | [Y7W]cGm | GCRRLCWKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Gastric cancer | CC50 : 3.9 ± 0.2 μM |
| dbacp00699 | [Y7W]cGm | GCRRLCWKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Breast cancer | CC50 : 3.9 ± 0.2 μM |
| dbacp00700 | [Y7W]cGm | GCRRLCWKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Cervical cancer | CC50 : 3.9 ± 0.2 μM |
| dbacp02395 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Epithelial cancer | CC50 : 39.8 ± 1.0 μM |
| dbacp02396 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Chronic myeloid leukemia | CC50 : 39.8 ± 1.0 μM |
| dbacp02397 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Gastric cancer | CC50 : 39.8 ± 1.0 μM |
| dbacp02398 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Breast cancer | CC50 : 39.8 ± 1.0 μM |
| dbacp02399 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Cervical cancer | CC50 : 39.8 ± 1.0 μM |
| dbacp02400 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Epithelial cancer | CC50 : 2.9 ± 0.1 μM |
| dbacp02401 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Chronic myeloid leukemia | CC50 : 2.9 ± 0.1 μM |
| dbacp02402 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Gastric cancer | CC50 : 2.9 ± 0.1 μM |
| dbacp02403 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Breast cancer | CC50 : 2.9 ± 0.1 μM |
| dbacp02404 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Cervical cancer | CC50 : 2.9 ± 0.1 μM |
| dbacp02405 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Epithelial cancer | CC50 : 71.7 ± 9.2 μM |
| dbacp02406 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Chronic myeloid leukemia | CC50 : 71.7 ± 9.2 μM |
| dbacp02407 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Gastric cancer | CC50 : 71.7 ± 9.2 μM |
| dbacp02408 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Breast cancer | CC50 : 71.7 ± 9.2 μM |
| dbacp02409 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Cervical cancer | CC50 : 71.7 ± 9.2 μM |
| dbacp02410 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Epithelial cancer | CC50 : > 64 μM |
| dbacp02411 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Chronic myeloid leukemia | CC50 : > 64 μM |
| dbacp02412 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Gastric cancer | CC50 : > 64 μM |
| dbacp02413 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Breast cancer | CC50 : > 64 μM |
| dbacp02414 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Cervical cancer | CC50 : > 64 μM |
| dbacp02415 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Epithelial cancer | CC50 : 15.3 ± 1.4 μM |
| dbacp02416 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Chronic myeloid leukemia | CC50 : 15.3 ± 1.4 μM |
| dbacp02417 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Gastric cancer | CC50 : 15.3 ± 1.4 μM |
| dbacp02418 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Breast cancer | CC50 : 15.3 ± 1.4 μM |
| dbacp02419 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Cervical cancer | CC50 : 15.3 ± 1.4 μM |
| dbacp02420 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Epithelial cancer | CC50 : 2.7 ± 0.1 μM |
| dbacp02421 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Chronic myeloid leukemia | CC50 : 2.7 ± 0.1 μM |
| dbacp02422 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Gastric cancer | CC50 : 2.7 ± 0.1 μM |
| dbacp02423 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Breast cancer | CC50 : 2.7 ± 0.1 μM |
| dbacp02424 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Cervical cancer | CC50 : 2.7 ± 0.1 μM |
| dbacp02425 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Epithelial cancer | CC50 : 12.7 ± 1.1 μM |
| dbacp02426 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Chronic myeloid leukemia | CC50 : 12.7 ± 1.1 μM |
| dbacp02427 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Gastric cancer | CC50 : 12.7 ± 1.1 μM |
| dbacp02428 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Breast cancer | CC50 : 12.7 ± 1.1 μM |
| dbacp02429 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Cervical cancer | CC50 : 12.7 ± 1.1 μM |
| dbacp03125 | Gomesin | ZCRRLCYKQRCVTYCRGR | Tarantula spider sp. | Target and destroy tumor cell membranes | Fluorescence-based assay using a Fluorescence Imaging Plate Reader | MM96L | Epithelial cancer | CC50 : 3.7 ± 0.2 μM |
| dbacp03126 | Gomesin | ZCRRLCYKQRCVTYCRGR | Tarantula spider sp. | Target and destroy tumor cell membranes | Fluorescence-based assay using a Fluorescence Imaging Plate Reader | K-562 | Chronic myeloid leukemia | CC50 : 3.8 ± 0.3 μM |
| dbacp03127 | Gomesin | ZCRRLCYKQRCVTYCRGR | Tarantula spider sp. | Target and destroy tumor cell membranes | Fluorescence-based assay using a Fluorescence Imaging Plate Reader | CRL-1739 | Gastric cancer | CC50 : 67.0 ± 5.0 μM |
| dbacp03128 | Gomesin | ZCRRLCYKQRCVTYCRGR | Tarantula spider sp. | Target and destroy tumor cell membranes | Fluorescence-based assay using a Fluorescence Imaging Plate Reader | HeLa | Cervical cancer | CC50 : 54.1 ± 5.0 μM |
| dbacp03129 | Gomesin | ZCRRLCYKQRCVTYCRGR | Tarantula spider sp. | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Epithelial cancer | CC50 : 3.8 ± 0.3 μM |
| dbacp03130 | Gomesin | ZCRRLCYKQRCVTYCRGR | Tarantula spider sp. | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Chronic myeloid leukemia | CC50 : 3.8 ± 0.3 μM |
| dbacp03131 | Gomesin | ZCRRLCYKQRCVTYCRGR | Tarantula spider sp. | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Gastric cancer | CC50 : 3.8 ± 0.3 μM |
| dbacp03132 | Gomesin | ZCRRLCYKQRCVTYCRGR | Tarantula spider sp. | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Breast cancer | CC50 : 3.8 ± 0.3 μM |
| dbacp03133 | Gomesin | ZCRRLCYKQRCVTYCRGR | Tarantula spider sp. | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Cervical cancer | CC50 : 3.8 ± 0.3 μM |
| dbacp03134 | Gomesin | ZCRRLCYKQRCVTYCRGR | Tarantula spider sp. | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Epithelial cancer | CC50 : 67.0 ± 5.0 μM |
| dbacp03135 | Gomesin | ZCRRLCYKQRCVTYCRGR | Tarantula spider sp. | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Chronic myeloid leukemia | CC50 : 67.0 ± 5.0 μM |
| dbacp03136 | Gomesin | ZCRRLCYKQRCVTYCRGR | Tarantula spider sp. | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Gastric cancer | CC50 : 67.0 ± 5.0 μM |
| dbacp03137 | Gomesin | ZCRRLCYKQRCVTYCRGR | Tarantula spider sp. | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Breast cancer | CC50 : 67.0 ± 5.0 μM |
| dbacp03138 | Gomesin | ZCRRLCYKQRCVTYCRGR | Tarantula spider sp. | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Cervical cancer | CC50 : 67.0 ± 5.0 μM |
| dbacp03139 | Gomesin | ZCRRLCYKQRCVTYCRGR | Tarantula spider sp. | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Epithelial cancer | CC50 : 3.7 ± 0.2 μM |
| dbacp03140 | Gomesin | ZCRRLCYKQRCVTYCRGR | Tarantula spider sp. | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Chronic myeloid leukemia | CC50 : 3.7 ± 0.2 μM |
| dbacp03141 | Gomesin | ZCRRLCYKQRCVTYCRGR | Tarantula spider sp. | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Gastric cancer | CC50 : 3.7 ± 0.2 μM |
| dbacp03142 | Gomesin | ZCRRLCYKQRCVTYCRGR | Tarantula spider sp. | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Breast cancer | CC50 : 3.7 ± 0.2 μM |
| dbacp03143 | Gomesin | ZCRRLCYKQRCVTYCRGR | Tarantula spider sp. | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Cervical cancer | CC50 : 3.7 ± 0.2 μM |
| dbacp03144 | Gomesin | ZCRRLCYKQRCVTYCRGR | Tarantula spider sp. | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Epithelial cancer | CC50 : 49.9 ±16.6 μM |
| dbacp03145 | Gomesin | ZCRRLCYKQRCVTYCRGR | Tarantula spider sp. | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Chronic myeloid leukemia | CC50 : 49.9 ±16.6 μM |
| dbacp03146 | Gomesin | ZCRRLCYKQRCVTYCRGR | Tarantula spider sp. | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Gastric cancer | CC50 : 49.9 ±16.6 μM |
| dbacp03147 | Gomesin | ZCRRLCYKQRCVTYCRGR | Tarantula spider sp. | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Breast cancer | CC50 : 49.9 ±16.6 μM |
| dbacp03148 | Gomesin | ZCRRLCYKQRCVTYCRGR | Tarantula spider sp. | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Cervical cancer | CC50 : 49.9 ±16.6 μM |
| dbacp03149 | Gomesin | ZCRRLCYKQRCVTYCRGR | Tarantula spider sp. | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Epithelial cancer | CC50 : 54.1 ± 5.0 μM |
| dbacp03150 | Gomesin | ZCRRLCYKQRCVTYCRGR | Tarantula spider sp. | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Chronic myeloid leukemia | CC50 : 54.1 ± 5.0 μM |
| dbacp03151 | Gomesin | ZCRRLCYKQRCVTYCRGR | Tarantula spider sp. | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Gastric cancer | CC50 : 54.1 ± 5.0 μM |
| dbacp03152 | Gomesin | ZCRRLCYKQRCVTYCRGR | Tarantula spider sp. | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Breast cancer | CC50 : 54.1 ± 5.0 μM |
| dbacp03153 | Gomesin | ZCRRLCYKQRCVTYCRGR | Tarantula spider sp. | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Cervical cancer | CC50 : 54.1 ± 5.0 μM |